Login to Your Account



EMA guides Alzheimer's trial design with use of new diagnostics criteria

By Nuala Moran
Staff Writer

Monday, February 8, 2016

LONDON – The EMA has released new guidelines for companies developing drugs to treat Alzheimer's disease, reflecting increased understanding of disease pathology and the availability of new diagnostic tools and biomarkers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription